UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 32.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,132 shares of the company's stock after purchasing an additional 36,341 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of Cellebrite DI worth $3,263,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also made changes to their positions in the company. USS Investment Management Ltd purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at about $706,000. Sphera Management Technology Funds Ltd acquired a new position in Cellebrite DI during the fourth quarter valued at $881,000. Two Sigma Advisers LP lifted its holdings in shares of Cellebrite DI by 35.0% in the 4th quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock valued at $39,899,000 after buying an additional 470,000 shares during the period. State of Wyoming raised its position in Cellebrite DI by 44.6% during the fourth quarter. State of Wyoming now owns 30,911 shares of the company's stock valued at $681,000 after acquiring an additional 9,530 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC acquired a new position in Cellebrite DI in the fourth quarter valued at approximately $4,583,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
CLBT has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a report on Friday. Lake Street Capital raised their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and an average target price of $22.43.
Get Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Price Performance
NASDAQ CLBT traded up $0.09 during mid-day trading on Monday, hitting $16.62. The stock had a trading volume of 1,284,644 shares, compared to its average volume of 1,480,137. The firm's 50 day moving average is $18.36 and its 200 day moving average is $20.08. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -11.96, a PEG ratio of 4.27 and a beta of 1.32. Cellebrite DI Ltd. has a twelve month low of $10.55 and a twelve month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The firm had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. During the same period last year, the firm posted $0.08 earnings per share. The company's revenue for the quarter was up 20.0% on a year-over-year basis. As a group, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
